PAY AS LITTLE AS $0

SUBJECT TO PATIENT AND PRESCRIPTION ELIGIBILITY*

See details below.

* Subject to eligibility and restrictions

Dovato
dolutegravir 50 mg/
lamivudine 300 mg tablets



GET STARTED TODAY!

This offer requires a one-time activation prior to use.
To activate, call 1-866-279-4705 or visit myviivcard.com

Prescription Processing Information:

RxBIN: 610524
RxPCN: Loyalty
RxGRP: 50777802
Issuer: 80840
ID#:

- **Present this coupon and, if applicable, your insurance card with your prescription for DOVATO at any participating pharmacy.**
- Eligible patients with valid commercial insurance that covers DOVATO may pay as little as $0 for each covered fill of DOVATO.
- This coupon may not be used by government beneficiaries, including but not limited to those enrolled in Medicare or Medicaid (see complete eligibility requirements for additional information).
- This coupon is nontransferable. Duplicates of this uniquely coded coupon are invalid and not redeemable at the pharmacy.
- **This coupon is not health insurance.**
- If you use a mail-order pharmacy, please contact your pharmacy provider to ensure this offer will be accepted.

For technical difficulties activating this card or other technical processing questions, please call the McKesson help desk at 1-866-747-1170, Monday - Friday 8:00 am - 8:00 pm ET, excluding holidays.

If you don't have prescription coverage, have questions about insurance coverage, or can't afford your medicines, visit ViiVConnect.com or call 1-844-588-3288 for more information about financial support programs.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Limit 1 per person. This card is nontransferable & not valid if reproduced. **This card is not health insurance.**

THIS CARD MAY BE USED FOR OTHER ViiV MEDICINES. See ViiVConnect.com/medicines for the list of eligible medicines and Prescribing Information.

- Present this card and, if applicable, your insurance card with your valid prescription at any participating pharmacy

ELIGIBILITY REQUIREMENTS: Patients who are enrolled in government healthcare prescription medicine programs, including, without limitation, Medicare Part D, Medicaid, VA, DOD, ADAP, state pharmaceutical assistance plans, CHAMPUS, or TRICARE, are not eligible.

TO THE PHARMACIST: Please submit the amount of co-pay authorized by the patient's primary insurance as a secondary transaction to McKesson Corporation (McKesson), ViiVConnect Savings Card's administrator. By redeeming this card, I certify that: (i) I have received this card from an eligible patient, (ii) I have dispensed the product as indicated, (iii) I have not submitted, and will not submit, a claim for reimbursement to the patient or any government-funded plan or program that serves as sole or primary insurer for the patient, (iv) I have not retained or provided to any person or entity any portion of the amount being made available to the patient, and (v) I will otherwise comply with the terms hereof. I further certify that my participation in this program is consistent with all applicable state laws and any obligations, contractual or otherwise, that I have as a pharmacy provider. It is a violation of federal law to buy, sell, or counterfeit this card.

TO THE HEALTHCARE PROFESSIONAL: If you are a healthcare professional who resides in Vermont, regularly practices in Vermont, or is licensed in Vermont, please do not download, print, or otherwise accept coupons or vouchers for ViiV Healthcare products.

TO THE PATIENT: No activation fee. This card is not valid if there are A/B generic drugs available via NDA or ANDA owners (excludes repackagers). Use must be consistent with terms of your health insurer drug benefit plan. You must report your use of this card to your health insurer if required. This card is the property of ViiV Healthcare and must be returned upon request. By redeeming this card, I, the Patient, certify that: (i) I have read and will comply with requirements, (ii) I am not enrolled in a government healthcare prescription medicine program, and agree to promptly notify McKesson at 1-866-747-1170 if I become enrolled in a government-funded pharmaceutical assistance plan or program after activation of this card, and (iii) I have not submitted and will not submit a claim for reimbursement to any government-funded plan or program. May not be used with any other discount or offer. Offer good only in USA, including Puerto Rico. Void where prohibited by law, taxed, or restricted. ViiV Healthcare (ViiV) and McKesson (on ViiV's behalf) reserve the right to rescind, revoke, or amend this card without notice.

Mail order: If you use a mail-order pharmacy, please contact your pharmacy provider to ensure that this offer will be accepted.

Please see www.DOVATO.com for more information and the full Prescribing Information, including Boxed Warning, for DOVATO. Please see Important Facts about DOVATO on accompanying sheet.

ViiV Healthcare

Trademarks are property of their respective owners.
©2025 ViiV Healthcare or licensor. PMUS-DLLCOUP240001 January 2025 Produced in USA.

Dovato
dolutegravir 50 mg/
lamivudine 300 mg tablets
(doe VAH toe)

IMPORTANT FACTS

This is only a brief summary of important information about DOVATO and does not replace talking to your healthcare provider about your condition and treatment.

MOST IMPORTANT INFORMATION ABOUT DOVATO

If you have both human immunodeficiency virus-1 (HIV-1) infection and Hepatitis B virus (HBV) infection, DOVATO can cause serious side effects, including:

- **Resistant HBV. Your healthcare provider will test you for HBV infection before you start treatment with DOVATO. If you have HIV-1 and hepatitis B, the HBV can change (mutate) during your treatment with DOVATO and become harder to treat (resistant). It is not known if DOVATO is safe and effective in people who have HIV-1 and HBV infection.**
- **Worsening of HBV infection.** If you have HBV infection and take DOVATO, your HBV may get worse (flare-up) if you stop taking DOVATO. A "flare-up" is when your HBV infection suddenly returns in a worse way than before.
  - Do not run out of DOVATO. Refill your prescription or talk to your healthcare provider before your DOVATO is all gone.
  - **Do not stop DOVATO without first talking to your healthcare provider.**
  - If you stop taking DOVATO, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver function and monitor your HBV infection. It may be necessary to give you a medicine to treat hepatitis B. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking DOVATO.

For more information about side effects, see "POSSIBLE SIDE EFFECTS OF DOVATO".

ABOUT DOVATO

DOVATO is a prescription medicine that is used without other HIV-1 medicines to treat HIV-1 infection in adults and adolescents 12 years of age and older who weigh at least 55 pounds (25 kg):

- who have not received HIV-1 medicines in the past, or
- to replace their current HIV-1 medicines when their healthcare provider determines that they meet certain requirements.

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). It is not known if DOVATO is safe and effective in children less than 12 years of age or weighing less than 55 pounds (25 kg).

DO NOT TAKE DOVATO IF YOU

- have ever had an allergic reaction to a medicine that contains dolutegravir or lamivudine.
- take dofetilide. Taking DOVATO and dofetilide can cause side effects that may be serious or life-threatening.

BEFORE TAKING DOVATO

Tell your healthcare provider about all of your medical conditions, including if you:

- have or have had liver problems, including hepatitis B or C infection.
- have kidney problems.
- are pregnant or plan to become pregnant. Talk to your healthcare provider about the benefits and risks of taking DOVATO during pregnancy.
- are breastfeeding or plan to breastfeed. DOVATO passes to your baby in your breast milk. Talk with your healthcare provider about the following risks to your baby from breastfeeding during treatment with DOVATO:
  - the HIV-1 virus may pass to your baby if your baby does not have HIV-1 infection.
  - the HIV-1 virus may become harder to treat if your baby has HIV-1 infection.
  - your baby may get side effects from DOVATO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines interact with DOVATO. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

BEFORE TAKING DOVATO (CONT'D)

- You can ask your healthcare provider or pharmacist for a list of medicines that interact with DOVATO.
- **Do not start taking a new medicine without telling your healthcare provider.** Your healthcare provider can tell you if it is safe to take DOVATO with other medicines.

POSSIBLE SIDE EFFECTS OF DOVATO

DOVATO can cause serious side effects, including:

- **See "MOST IMPORTANT INFORMATION ABOUT DOVATO".**
- **Allergic reactions. Call your healthcare provider right away if you develop a rash with DOVATO. Stop taking DOVATO and get medical help right away if you develop a rash with any of the following signs or symptoms:** fever; generally ill feeling; tiredness; muscle or joint aches; blisters or sores in mouth; blisters or peeling of the skin; redness or swelling of the eyes; swelling of the mouth, face, lips, or tongue; problems breathing.
- **Liver problems. People with a history of hepatitis B or C virus may have an increased risk of developing new or worsening changes in certain liver tests during treatment with DOVATO. Liver problems, including liver failure, have also happened in people without a history of liver disease or other risk factors. Your healthcare provider may do blood tests to check your liver.**
  Tell your healthcare provider right away if you get any of the following signs or symptoms of liver problems: your skin or the white part of your eyes turns yellow (jaundice); dark or "tea-colored" urine; light-colored stools (bowel movements); nausea or vomiting; loss of appetite; and/or pain, aching, or tenderness on the right side of your stomach area.
- **Too much lactic acid in your blood (lactic acidosis). Too much lactic acid is a serious medical emergency that can lead to death. Tell your healthcare provider right away if you get any of the following symptoms that could be signs of lactic acidosis:** feel very weak or tired; unusual (not normal) muscle pain; trouble breathing; stomach pain with nausea and vomiting; feel cold, especially in your arms and legs; feel dizzy or lightheaded; and/or a fast or irregular heartbeat.
- **Lactic acidosis can also lead to severe liver problems, which can lead to death. Your liver may become large (hepatomegaly) and you may develop fat in your liver (steatosis). Tell your healthcare provider right away if you get any of the signs or symptoms of liver problems which are listed above under "Liver problems". You may be more likely to get lactic acidosis or severe liver problems if you are female or very overweight (obese).**
- **Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after you start taking DOVATO.**
- **The most common side effects of DOVATO include:** headache; nausea; diarrhea; trouble sleeping; tiredness; and anxiety.

These are not all the possible side effects of DOVATO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

GET MORE INFORMATION

- Talk to your healthcare provider or pharmacist.
- Go to DOVATO.com or call 1-877-844-8872, where you can also get FDA-approved labeling.

April 2024 DVT:14PI-11PIL
Trademark is owned by or licensed to the ViiV Healthcare group of companies.
©2024 ViiV Healthcare or licensor.
PMUS-DLLBRFS240001 April 2024 Produced in USA. 0002-0031-17